ProQR to Present at Three Scientific Conferences in April Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., April 22, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. April 22, 2019
ProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., April 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. April 18, 2019
ProQR Announces Annual Meeting of Shareholders Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., April 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. April 18, 2019
ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10 Press release LEIDEN, The Netherlands and CAMBRIDGE, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. April 15, 2019
ProQR to Present at the H.C. Wainwright Global Life Sciences Conference Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., April 01, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. April 01, 2019
ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. March 26, 2019
ProQR traite le premier patient dans l’essai STELLAR de Phase 1/2 du QR-421a pour le syndrome d’Usher de type 2 Press release LEIDEN, Pays-Bas et CAMBRIDGE, Massachusetts, 11 mars 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. March 11, 2019
ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2 Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. March 11, 2019
ProQR to Present at Cowen Health Care Conference Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. March 05, 2019
ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results Press release LEIDEN, The Netherlands & CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. February 27, 2019